We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · July 20, 2020

Effects of Lixisenatide vs Liraglutide on Esophageal and Gastric Function in Type 2 Diabetes

Diabetes Care


Additional Info

Diabetes Care
Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes
Diabetes Care 2020 Jul 09;[EPub Ahead of Print], DR Quast, N Schenker, BA Menge, MA Nauck, C Kapitza, JJ Meier

Further Reading